Zobrazeno 1 - 10
of 38
pro vyhledávání: '"F, deBraud"'
Autor:
Massimo Zucchetti, F. Debraud, Maurizio D'Incalci, Andrew R. Allen, Josep Tabernero, B. Adamo, Ratislav Bahleda, Renata Robert, Angelo Delmonte, M. G. Camboni, Jean-Charles Soria, R. Dientsmann, Fabrice Andre, Jeffrey D. Isaacson, C. Saba, Jason B. Litten, Roberta Cereda, F. Dubois
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(11)
Background Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor receptor types α and β (PGFRα/β), which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d996f8e8b1f4d889e388989e50e7bea
https://pubmed.ncbi.nlm.nih.gov/32590894
https://pubmed.ncbi.nlm.nih.gov/32590894
Autor:
Marina Ziche, F. DeBraud, Federico Bussolino, Adriana Albini, Alberto Costa, Raffaella Giavazzi, Marco Presta
Publikováno v:
European Journal of Cancer. 36:1913-1918
Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy National Institute for Cancer Research, Genoa, Italy Institute for Cancer Research and Treatment, University of Turin, Italy European Institute of Oncology, Milan, I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30fff9ea6554c1d328ca2d997aab3d9f
https://doi.org/10.1016/s0959-8049(00)00276-8
https://doi.org/10.1016/s0959-8049(00)00276-8
Publikováno v:
Oncology reports. 1(1)
The role of medical treatment in advanced or metastatic malignant melanoma is still controversial, and there is no standard systemic therapy. Dacarbazine has been the most widely used single drug, despite its response rate range of 10-25%. A number o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d67627b1b34d5fab308f371ba11dd675
https://pubmed.ncbi.nlm.nih.gov/21607311
https://pubmed.ncbi.nlm.nih.gov/21607311
Publikováno v:
International journal of oncology. 2(2)
The medical treatment of advanced or metastatic malignant melanoma is still controversial and no standard systemic therapy can be claimed. The selection of patients is an important factor to evaluate the results from clinical trials. Among the chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e496f3df8b1f0fc7e038e7aa020094c
https://pubmed.ncbi.nlm.nih.gov/21573545
https://pubmed.ncbi.nlm.nih.gov/21573545
Autor:
Fabrice Andre, F. Dubois, Angelo Delmonte, J-C. Soria, Josep Tabernero, Renata Robert, B. Adamo, Andrew R. Allen, Ratislav Bahleda, Rodrigo Dienstmann, M. G. Camboni, Maurizio D'Incalci, Jeffrey D. Isaacson, Massimo Zucchetti, F. Debraud, C. Saba, Roberta Cereda, Jason B. Litten
Publikováno v:
Annals of Oncology. 26:445
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8d819b7c1358457219b3f2145fcab0
https://doi.org/10.1093/annonc/mdu547
https://doi.org/10.1093/annonc/mdu547
Publikováno v:
American journal of clinical oncology. 21(3)
From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study. Thirteen received oxaliplatin alone and 12 received it in combination with 5-FU. Oxalipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec25b5e7c3f4da4297566d9b447dfd7d
https://pubmed.ncbi.nlm.nih.gov/9626798
https://pubmed.ncbi.nlm.nih.gov/9626798
Autor:
A. Longhi, F Debraud, Marco Colleoni, Franco Nolè, Nicoletta Zilembo, M.G. Zampino, Emilio Bajetta
Publikováno v:
Oncology Reports.
The role of medical treatment in advanced or metastatic malignant melanoma is still controversial, and there is no standard systemic therapy. Dacarbazine has been the most widely used single drug, despite its response rate range of 10-25%. A number o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b97f4c43e7f2125f6ba8c8630c14291d
https://doi.org/10.3892/or.1.1.83
https://doi.org/10.3892/or.1.1.83
Autor:
A. Zubel, Igor Bondarenko, F. DeBraud, Ilhan Celik, P. Koralewski, J.T. Hartmann, Carsten Bokemeyer, G. Schuch
Publikováno v:
European Journal of Cancer Supplements. 7:346
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ad1532cde5f8c1466f267fc79931ebf
https://doi.org/10.1016/s1359-6349(09)71174-7
https://doi.org/10.1016/s1359-6349(09)71174-7
Publikováno v:
Cancer treatment and research. 52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28f9fd96353798a06c8ec96cc776a6b7
https://pubmed.ncbi.nlm.nih.gov/1976368
https://pubmed.ncbi.nlm.nih.gov/1976368
Autor:
Alberto Sobrero, Patrick Schöffski, Charles Butts, Chris Twelves, Arie Figer, E. Van Cutsem, Eduardo Díaz-Rubio, Th. Conroy, Johannes Grossmann, J. Tabernero, J. Cassidy, F. DeBraud
Publikováno v:
European Journal of Cancer. 37:S272
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f75f99dfce9182377d9aa238879c3141
https://doi.org/10.1016/s0959-8049(01)81497-0
https://doi.org/10.1016/s0959-8049(01)81497-0